Company Encyclopedia
View More
name
Evoke Pharma
EVOK.US
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
4.362 T
EVOK.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking97/182
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-134.88%E
    • Profit Margin-36.23%E
    • Gross Margin97.62%A
  • Growth ScoreB
    • Revenue YoY67.40%A
    • Net Profit YoY14.98%B
    • Total Assets YoY10.57%B
    • Net Assets YoY-23.36%E
  • Cash ScoreC
    • Cash Flow Margin-276.01%D
    • OCF YoY67.40%A
  • Operating ScoreA
    • Turnover0.97A
  • Debt ScoreE
    • Gearing Ratio78.52%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    12:20 ET Halper Sadeh LLC Encourages AXTA, COMP, EVOK, JTAI Shareholders to Contact the Firm to Discuss Their Rights

    Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws by Axalta Coating Systems, Compass Inc., Evoke Pharma, and Jet.AI. The firm encourages shareholders to contact them to discuss their rights, as they may seek increased consideration, additional disclosures, or other relief on behalf of shareholders. The investigations relate to recent sales and mergers involving these companies.

    prnewswire·
    US
    AXTA
    +5.05%
    US
    COMP
    +8.61%
    US
    EVOK
    -0.19%
    prnewswire·
    US
    AXTA
    +5.05%
    US
    COMP
    +8.61%
    US
    EVOK
    -0.19%

    Evoke Pharma Reports Increased Sales Amid Ongoing Losses

    Evoke Pharma Inc reported increased Q3 net product sales of $4.28 million, up from $2.65 million in 2024, but faced a net loss of $1.16 million due to rising operating expenses. Cash reserves decreased to $11.58 million. The company anticipates ongoing losses and is seeking additional funding to support Gimoti's commercialization and clinical trials.

    Tip Ranks·
    US
    EVOK
    -0.19%
    Tip Ranks·
    US
    EVOK
    -0.19%

    20:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-COMP, HFWA, EVOK, and JTAI

    Class Action Attorney Juan Monteverde of Monteverde & Associates PC is investigating mergers involving Compass, Heritage Financial, Evoke Pharma, and Jet.AI. The firm, recognized as a top securities class action firm, has recovered millions for shareholders. The investigations focus on the terms and shareholder impacts of these mergers. Shareholders can obtain more information at no cost.

    prnewswire·
    US
    HFWA
    +4.26%
    US
    EVOK
    -0.19%
    prnewswire·
    US
    HFWA
    +4.26%
    US
    EVOK
    -0.19%

    Evoke Pharma’s Merger Uncertainty: Potential Risks to Business Operations and Financial Health

    Evoke Pharma Inc (EVOK) faces significant risks due to a pending merger, which could disrupt business operations and financial health. The uncertainty may affect employee motivation, management focus, and relationships with key stakeholders. These disruptions could negatively impact financial results and stock performance. Wall Street has a Hold consensus rating on EVOK stock.

    Tip Ranks·
    US
    EVOK
    -0.19%
    Tip Ranks·
    US
    EVOK
    -0.19%

    17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-HBAN, AVDL, EVOK, and TRUE

    Monteverde & Associates PC, a top class action firm, is investigating mergers involving Huntington Bancshares, Avadel Pharmaceuticals, Evoke Pharma, and TrueCar. The firm aims to recover money for shareholders, offering free consultations. Each merger has specific terms for shareholder compensation. Contact Juan Monteverde for more information.

    prnewswire·
    US
    TRUE
    -1.42%
    US
    HBAN
    +3.66%
    US
    AVDL
    +0.39%
    prnewswire·
    US
    TRUE
    -1.42%
    US
    HBAN
    +3.66%
    US
    AVDL
    +0.39%